IN2014DN02346A - - Google Patents
Info
- Publication number
- IN2014DN02346A IN2014DN02346A IN2346DEN2014A IN2014DN02346A IN 2014DN02346 A IN2014DN02346 A IN 2014DN02346A IN 2346DEN2014 A IN2346DEN2014 A IN 2346DEN2014A IN 2014DN02346 A IN2014DN02346 A IN 2014DN02346A
- Authority
- IN
- India
- Prior art keywords
- dosage forms
- oral dosage
- compositions
- enylamino
- chloro
- Prior art date
Links
- 239000006186 oral dosage form Substances 0.000 abstract 2
- 125000004899 1-ethylpropylamino group Chemical group C(C)C(CC)N* 0.000 abstract 1
- VRSJISPNKABXPI-UHFFFAOYSA-N 2-hydroxy-n-methoxy-n-methylbenzenesulfonamide Chemical compound CON(C)S(=O)(=O)C1=CC=CC=C1O VRSJISPNKABXPI-UHFFFAOYSA-N 0.000 abstract 1
- 206010027654 Allergic conditions Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 abstract 1
- 229960001231 choline Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530516P | 2011-09-02 | 2011-09-02 | |
| PCT/IB2012/054502 WO2013030803A1 (en) | 2011-09-02 | 2012-08-31 | Choline salt of an anti - inflammatory substituted cyclobutenedione compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN02346A true IN2014DN02346A (enExample) | 2015-05-15 |
Family
ID=47116123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2346DEN2014 IN2014DN02346A (enExample) | 2011-09-02 | 2012-08-31 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9018261B2 (enExample) |
| EP (2) | EP3287438A1 (enExample) |
| JP (3) | JP2014529621A (enExample) |
| KR (1) | KR102024955B1 (enExample) |
| CN (1) | CN103842330B (enExample) |
| BR (1) | BR112014004963A2 (enExample) |
| CA (1) | CA2846510C (enExample) |
| EA (1) | EA201490552A1 (enExample) |
| ES (1) | ES2655942T3 (enExample) |
| HU (1) | HUE035751T2 (enExample) |
| IN (1) | IN2014DN02346A (enExample) |
| MX (1) | MX359259B (enExample) |
| NO (1) | NO2679622T3 (enExample) |
| PL (1) | PL2760821T3 (enExample) |
| PT (1) | PT2760821T (enExample) |
| SI (1) | SI2760821T1 (enExample) |
| WO (1) | WO2013030803A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| KR20200089286A (ko) | 2017-11-16 | 2020-07-24 | 노파르티스 아게 | 조합 요법 |
| CN111867579B (zh) | 2018-01-08 | 2023-11-24 | 凯莫森特里克斯股份有限公司 | Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| JP2022514315A (ja) | 2018-12-20 | 2022-02-10 | ノバルティス アーゲー | ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ |
| AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US20230057071A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| CN118806759A (zh) * | 2020-04-24 | 2024-10-22 | 福尔克博士药物有限责任公司 | 用于tg2相关疾病的吡啶酮衍生物的全身性制剂 |
| JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン |
| CN116134027B (zh) | 2020-08-03 | 2025-01-24 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506252A (en) | 1993-11-17 | 1996-04-09 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| NZ294762A (en) | 1994-11-16 | 1998-11-25 | American Home Prod | Diaminocyclobutene-3,4-dione derivatives, preparation and pharmaceutical compositions thereof |
| WO1998033763A1 (en) | 1997-01-30 | 1998-08-06 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| US5840764A (en) | 1997-01-30 | 1998-11-24 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| US6166050A (en) | 1998-12-14 | 2000-12-26 | American Home Products Corporation | 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4 |
| FR2815345B1 (fr) | 2000-10-12 | 2002-12-13 | Servier Lab | Nouveaux derives de cyclobutene-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB0028844D0 (en) | 2000-11-27 | 2001-01-10 | Celltech Chiroscience Ltd | Chemical compounds |
| JP2004520412A (ja) | 2001-01-16 | 2004-07-08 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ−８受容体アンタゴニスト |
| WO2002057230A1 (en) | 2001-01-16 | 2002-07-25 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| US20030175349A1 (en) * | 2001-01-30 | 2003-09-18 | Council Of Scientific And Industrial Research | Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient |
| EP1358160A1 (en) | 2001-02-07 | 2003-11-05 | Abbott Laboratories | Aminal diones as potassium channel openers |
| JP2005507366A (ja) | 2001-03-30 | 2005-03-17 | スミスクライン・ビーチャム・コーポレイション | フェノール含有化合物の合成方法 |
| US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| DK1381590T3 (da) | 2001-04-16 | 2007-10-22 | Schering Corp | 3,4-disubstituerede cyclobuten-1,2-dioner som CXC-kemokinreceptorligander |
| US20040097547A1 (en) | 2001-04-16 | 2004-05-20 | Taveras Arthur G. | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US20050080112A1 (en) | 2001-06-22 | 2005-04-14 | Madsen Lars Siim | Compounds for use in disorders associated with mast cell or basophil acitvity |
| US20040053953A1 (en) | 2002-03-18 | 2004-03-18 | Schering Corporation | Treatment of chemokine mediated diseases |
| WO2005004915A2 (en) * | 2003-07-09 | 2005-01-20 | Boehringer Ingelheim International Gmbh | Compositions comprising meloxicam |
| JP2007519751A (ja) | 2004-01-30 | 2007-07-19 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターリガンドの結晶多形 |
| WO2005076987A2 (en) * | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
| US7635694B2 (en) | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
| GB0407908D0 (en) * | 2004-04-07 | 2004-05-12 | Univ York | Ionic liquids |
| DE102004046492A1 (de) | 2004-09-23 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| ATE432921T1 (de) | 2004-12-23 | 2009-06-15 | Gpc Biotech Ag | Quadratsäurederivate mit antiproliferativer wirkung |
| DE102005001053A1 (de) | 2005-01-07 | 2006-07-20 | Merck Patent Gmbh | Quadratsäurederivate |
| WO2006084661A1 (de) | 2005-02-10 | 2006-08-17 | Wacker Chemie Ag | Lacke enthaltend partikel mit geschützten isocyanatgruppen |
| JP4688889B2 (ja) | 2005-02-16 | 2011-05-25 | シェーリング コーポレイション | Ｃｘｃｒ３アンタゴニスト活性を有する、アミン結合ピリジルおよびフェニルで置換されたピペラジン−ピペリジン |
| DE102005035742A1 (de) | 2005-07-29 | 2007-02-01 | Merck Patent Gmbh | Quadratsäurederivate II |
| DE102005035741A1 (de) | 2005-07-29 | 2007-02-08 | Merck Patent Gmbh | Quadratsäurederivate |
| US20080045489A1 (en) | 2006-07-07 | 2008-02-21 | Jianhua Chao | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| US8450348B2 (en) | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
| WO2008109181A2 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| US8183281B2 (en) | 2007-06-06 | 2012-05-22 | Novartis Ag | CXC-chemokine receptor ligands |
| US8519168B2 (en) | 2007-07-03 | 2013-08-27 | Merck Sharp & Dohme Corp. | Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |
| US20100249439A1 (en) | 2007-07-05 | 2010-09-30 | Vincenzo Liotta | Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |
| WO2009012375A2 (en) | 2007-07-19 | 2009-01-22 | Wyeth | Squarate kinase inhibitors |
| MX2010006089A (es) | 2007-12-04 | 2010-09-22 | Schering Corp | Metodos de tratamiento de enfermedad pulmonar obstructiva cronica. |
| AR069637A1 (es) | 2007-12-10 | 2010-02-10 | Novartis Ag | Derivados de pirazinas |
| JP2011526888A (ja) * | 2008-07-01 | 2011-10-20 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 治療薬を標的送達するための経口速溶性薄膜 |
| TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| PT2307376E (pt) | 2008-08-04 | 2016-02-26 | Merck Patent Gmbh | Novos compostos de fenilamino-isonicotinamida |
| WO2010057036A2 (en) * | 2008-11-14 | 2010-05-20 | Portola Pharmaceuticals, Inc. | Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof |
| WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| WO2010091543A1 (en) | 2009-02-10 | 2010-08-19 | Merck Sharp & Dohme Corp. | Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists |
-
2012
- 2012-08-31 CN CN201280047528.3A patent/CN103842330B/zh not_active Expired - Fee Related
- 2012-08-31 EP EP17191365.0A patent/EP3287438A1/en not_active Withdrawn
- 2012-08-31 EP EP12780535.6A patent/EP2760821B1/en not_active Not-in-force
- 2012-08-31 EA EA201490552A patent/EA201490552A1/ru unknown
- 2012-08-31 PT PT127805356T patent/PT2760821T/pt unknown
- 2012-08-31 HU HUE12780535A patent/HUE035751T2/hu unknown
- 2012-08-31 CA CA2846510A patent/CA2846510C/en not_active Expired - Fee Related
- 2012-08-31 MX MX2014002492A patent/MX359259B/es active IP Right Grant
- 2012-08-31 BR BR112014004963A patent/BR112014004963A2/pt active Search and Examination
- 2012-08-31 IN IN2346DEN2014 patent/IN2014DN02346A/en unknown
- 2012-08-31 ES ES12780535.6T patent/ES2655942T3/es active Active
- 2012-08-31 PL PL12780535T patent/PL2760821T3/pl unknown
- 2012-08-31 SI SI201231173T patent/SI2760821T1/en unknown
- 2012-08-31 WO PCT/IB2012/054502 patent/WO2013030803A1/en not_active Ceased
- 2012-08-31 US US14/241,306 patent/US9018261B2/en not_active Expired - Fee Related
- 2012-08-31 JP JP2014527801A patent/JP2014529621A/ja active Pending
- 2012-08-31 KR KR1020147008317A patent/KR102024955B1/ko not_active Expired - Fee Related
-
2013
- 2013-06-26 NO NO13173884A patent/NO2679622T3/no unknown
-
2016
- 2016-09-08 JP JP2016175348A patent/JP6612200B2/ja not_active Expired - Fee Related
-
2018
- 2018-07-19 JP JP2018135448A patent/JP2019001787A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2760821A1 (en) | 2014-08-06 |
| JP6612200B2 (ja) | 2019-11-27 |
| EP2760821B1 (en) | 2017-10-11 |
| BR112014004963A2 (pt) | 2017-03-21 |
| NO2679622T3 (enExample) | 2018-01-20 |
| KR102024955B1 (ko) | 2019-09-24 |
| US20140206768A1 (en) | 2014-07-24 |
| PT2760821T (pt) | 2018-01-11 |
| JP2014529621A (ja) | 2014-11-13 |
| HUE035751T2 (hu) | 2018-08-28 |
| PL2760821T3 (pl) | 2018-04-30 |
| EP3287438A1 (en) | 2018-02-28 |
| CN103842330A (zh) | 2014-06-04 |
| CA2846510A1 (en) | 2013-03-07 |
| JP2019001787A (ja) | 2019-01-10 |
| MX2014002492A (es) | 2014-05-28 |
| CN103842330B (zh) | 2016-10-19 |
| KR20140059264A (ko) | 2014-05-15 |
| MX359259B (es) | 2018-09-20 |
| EA201490552A1 (ru) | 2014-11-28 |
| JP2017025081A (ja) | 2017-02-02 |
| WO2013030803A1 (en) | 2013-03-07 |
| SI2760821T1 (en) | 2018-02-28 |
| ES2655942T3 (es) | 2018-02-22 |
| CA2846510C (en) | 2019-10-22 |
| US9018261B2 (en) | 2015-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN02346A (enExample) | ||
| AU2018201997B2 (en) | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions | |
| MX349159B (es) | Derivados deuterados de ivacaftor. | |
| IN2014MN00988A (enExample) | ||
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| GT201400016A (es) | Indazoles | |
| IN2014MN00948A (enExample) | ||
| EP2552203A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF VIRUS INFECTIONS | |
| CA2818187C (en) | Bromodomain inhibitors and uses thereof | |
| UA111770C2 (uk) | Інгібітори бромдомену | |
| WO2012116290A3 (en) | Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| HK1206264A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
| CR20140134A (es) | Composiciones farmacéuticas | |
| UA109667C2 (xx) | Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| IN2014MN00987A (enExample) | ||
| IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
| BR112013019256A2 (pt) | inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune | |
| EP2696874A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF NOSES | |
| BR112013029730A2 (pt) | composição farmacêutica de rosuvastatina cálcica | |
| EP3060220A4 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| EA201590726A1 (ru) | Лахинимод для уменьшения таламического поражения при рассеянном склерозе | |
| UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
| FR2981572B1 (fr) | Compositions pharmaceutiques d'acide ursodesoxycholique |